OLMA Quote, Financials, Valuation and Earnings

Cogent Biosciences, Inc. has a net margin of -- compared to Olema Pharmaceuticals, Inc.'s net margin of --. Olema Pharmaceuticals, Inc.'s return on equity of -45.61% beat Cogent Biosciences, Inc.'s return on equity of -104.81%.

Olema Pharmaceuticals, Inc. has a consensus price target of $46.09, signalling upside risk potential of 90.46%. On the other hand Cogent Biosciences, Inc. has an analysts' consensus of $53.83 which suggests that it could grow by 38.57%. Given that Olema Pharmaceuticals, Inc. has higher upside potential than Cogent Biosciences, Inc., analysts believe Olema Pharmaceuticals, Inc. is more attractive than Cogent Biosciences, Inc..

Olema Pharmaceuticals, Inc. has a beta of 1.926, which suggesting that the stock is 92.554% more volatile than S&P 500. In comparison Cogent Biosciences, Inc. has a beta of 0.468, suggesting its less volatile than the S&P 500 by 53.231%.

Olema Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cogent Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olema Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Cogent Biosciences, Inc. pays out -- of its earnings as a dividend.

Olema Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Cogent Biosciences, Inc. quarterly revenues of --. Olema Pharmaceuticals, Inc.'s net income of -$42.2M is higher than Cogent Biosciences, Inc.'s net income of -$102.5M. Notably, Olema Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Cogent Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals, Inc. is -- versus 55.99x for Cogent Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Corvus Pharmaceuticals, Inc. has a net margin of -- compared to Olema Pharmaceuticals, Inc.'s net margin of --. Olema Pharmaceuticals, Inc.'s return on equity of -45.61% beat Corvus Pharmaceuticals, Inc.'s return on equity of -30.6%.

Olema Pharmaceuticals, Inc. has a consensus price target of $46.09, signalling upside risk potential of 90.46%. On the other hand Corvus Pharmaceuticals, Inc. has an analysts' consensus of $33.33 which suggests that it could grow by 91.68%. Given that Corvus Pharmaceuticals, Inc. has higher upside potential than Olema Pharmaceuticals, Inc., analysts believe Corvus Pharmaceuticals, Inc. is more attractive than Olema Pharmaceuticals, Inc..

Olema Pharmaceuticals, Inc. has a beta of 1.926, which suggesting that the stock is 92.554% more volatile than S&P 500. In comparison Corvus Pharmaceuticals, Inc. has a beta of 0.786, suggesting its less volatile than the S&P 500 by 21.448%.

Olema Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corvus Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olema Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Corvus Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Olema Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Corvus Pharmaceuticals, Inc. quarterly revenues of --. Olema Pharmaceuticals, Inc.'s net income of -$42.2M is lower than Corvus Pharmaceuticals, Inc.'s net income of -$10.2M. Notably, Olema Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Corvus Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals, Inc. is -- versus -- for Corvus Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Oric Pharmaceuticals, Inc. has a net margin of -- compared to Olema Pharmaceuticals, Inc.'s net margin of --. Olema Pharmaceuticals, Inc.'s return on equity of -45.61% beat Oric Pharmaceuticals, Inc.'s return on equity of -41.02%.

Olema Pharmaceuticals, Inc. has a consensus price target of $46.09, signalling upside risk potential of 90.46%. On the other hand Oric Pharmaceuticals, Inc. has an analysts' consensus of $21.23 which suggests that it could grow by 57.85%. Given that Olema Pharmaceuticals, Inc. has higher upside potential than Oric Pharmaceuticals, Inc., analysts believe Olema Pharmaceuticals, Inc. is more attractive than Oric Pharmaceuticals, Inc..

Olema Pharmaceuticals, Inc. has a beta of 1.926, which suggesting that the stock is 92.554% more volatile than S&P 500. In comparison Oric Pharmaceuticals, Inc. has a beta of 1.280, suggesting its more volatile than the S&P 500 by 27.972%.

Olema Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oric Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olema Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Oric Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Olema Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Oric Pharmaceuticals, Inc. quarterly revenues of --. Olema Pharmaceuticals, Inc.'s net income of -$42.2M is lower than Oric Pharmaceuticals, Inc.'s net income of -$30.5M. Notably, Olema Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Oric Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals, Inc. is -- versus -- for Oric Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protagonist Therapeutics, Inc. has a net margin of -- compared to Olema Pharmaceuticals, Inc.'s net margin of -596.8%. Olema Pharmaceuticals, Inc.'s return on equity of -45.61% beat Protagonist Therapeutics, Inc.'s return on equity of -19.76%.

Olema Pharmaceuticals, Inc. has a consensus price target of $46.09, signalling upside risk potential of 90.46%. On the other hand Protagonist Therapeutics, Inc. has an analysts' consensus of $104.17 which suggests that it could grow by 13.13%. Given that Olema Pharmaceuticals, Inc. has higher upside potential than Protagonist Therapeutics, Inc., analysts believe Olema Pharmaceuticals, Inc. is more attractive than Protagonist Therapeutics, Inc..

Olema Pharmaceuticals, Inc. has a beta of 1.926, which suggesting that the stock is 92.554% more volatile than S&P 500. In comparison Protagonist Therapeutics, Inc. has a beta of 2.235, suggesting its more volatile than the S&P 500 by 123.482%.

Olema Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protagonist Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olema Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Protagonist Therapeutics, Inc. pays out -- of its earnings as a dividend.

Olema Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Protagonist Therapeutics, Inc. quarterly revenues of $7.4M. Olema Pharmaceuticals, Inc.'s net income of -$42.2M is higher than Protagonist Therapeutics, Inc.'s net income of -$44.4M. Notably, Olema Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Protagonist Therapeutics, Inc.'s PE ratio is 137.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals, Inc. is -- versus 127.21x for Protagonist Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.